Loading the Newsroom

What China’s first approval ahead of major regulators means for biopharma strategy, timelines, and competitive pressure.

A new nonprofit aims to streamline gene therapy for rare diseases pharma often sidesteps, reshaping how treatments get built, sold, and approved.

Summer Farmen turned an ALK-positive diagnosis into a six-year survival case study on targeted therapy and patient power.

The newborn-brain-injury biotech is betting on Hong Kong capital markets before a later US secondary listing.